XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

NCT06936527 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ENROLLING_BY_INVITATION

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer
Metastatic Colorectal Cancer With RAS Mutation

Interventions

BIOLOGICAL: Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI
BIOLOGICAL: Drug: XS-03
BIOLOGICAL: Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI

Sponsor

NovaOnco Therapeutics Co., Ltd.